Tirzepatide Is Now Being Tested for Type 1 Diabetes and Alcohol Use Disorder. Here's Why That's Wild.

Tirzepatide made headlines for weight loss. people lost an average of 22.5% of their body weight in the SURMOUNT-1 trial. That's dropping from 100kg to 77.5kg without surgery. No other drug has come close to that number. But in 2026, researchers are testing it for conditions nobody saw coming: type 1 diabetes and alcohol use disorder. Let's talk about why.

What tirzepatide actually does

Tirzepatide is a dual GLP-1/GIP receptor agonist. Translation: it mimics two hormones your gut naturally produces when you eat.

GLP-1 (glucagon-like peptide-1) tells your brain you're full, slows stomach emptying, and stimulates insulin release when blood sugar rises.

GIP (glucose-dependent insulinotropic polypeptide) also stimulates insulin and seems to enhance fat metabolism.

Together, they create the most powerful weight loss effect any drug has produced. But the GLP-1 pathway does more than control appetite. it regulates reward pathways in your brain. That's where the alcohol trial comes in.

Type 1 diabetes: the trial nobody expected

Type 1 diabetes is an autoimmune disease where your pancreas stops producing insulin. It's not caused by obesity or lifestyle. You have to inject insulin for life. So why test tirzepatide, a drug designed for type 2 diabetes and obesity?

Because type 1 diabetics with obesity face unique challenges.

Insulin therapy itself can cause weight gain. More insulin means more fat storage. That weight gain worsens insulin resistance, which means you need even more insulin. It's a vicious cycle.

A Phase 2 trial (NCT06914895) is now testing tirzepatide in adults with type 1 diabetes and obesity or overweight. It's recruiting across 80+ locations worldwide. U.S., Canada, Europe, Australia, Mexico, Israel, Taiwan.

The hypothesis: tirzepatide could help type 1 diabetics lose weight and improve insulin sensitivity without compromising blood sugar control. If it works, it would be the first drug to address both problems simultaneously in this population.

Alcohol use disorder: targeting the reward pathway

This one surprised everyone. A Phase 2 trial (NCT06994338) is testing whether tirzepatide reduces alcohol consumption compared to placebo.

Why would a weight loss drug affect drinking?

Because GLP-1 receptors exist throughout your brain's reward system. the same circuits that drive alcohol, drug, and food cravings. When you activate GLP-1 receptors, you dampen those reward signals.

Early animal studies showed GLP-1 agonists reduce alcohol-seeking behavior in rats. Anecdotal reports from people on semaglutide (Ozempic/Wegovy) and tirzepatide suggest they spontaneously drink less. not because they decided to quit, but because alcohol just became less appealing.

If the trial shows significant reduction in alcohol consumption, it would open a massive new indication for GLP-1 drugs. Alcohol use disorder affects 29.5 million Americans. Current treatments (naltrexone, acamprosate, disulfiram) work for some people but have limited efficacy.

Weight maintenance: the relapse problem

Another 2026 trial (NCT04660643) tackled the question everyone asks: what happens when you stop?

Participants took tirzepatide (10mg or 15mg) for 36 weeks, then either continued or switched to placebo for another 52 weeks.

The results: people who stayed on tirzepatide maintained their weight loss. People who switched to placebo regained weight. but not all of it. Some metabolic improvements persisted even after stopping.

This matters because GLP-1 drugs are expensive, insurance coverage is patchy, and most people can't stay on them forever. Understanding what happens after you stop helps clinicians design better protocols.

Combination therapy: pushing past the plateau

The newest trial tests tirzepatide + mibavademab to see if combining drugs produces greater weight loss than tirzepatide alone.

Why combine? Because even tirzepatide has a plateau. Most people lose 15-25% of their body weight, then hit a wall. Some need to lose more for health reasons (severe obesity, metabolic syndrome, pre-surgery preparation).

Mibavademab is a monoclonal antibody targeting a different pathway. The hypothesis: by hitting two separate mechanisms, you might break through the plateau and achieve greater weight loss without increasing side effects.

If combination therapy works, it would establish a new standard. like how oncologists combine chemotherapy drugs to attack cancer from multiple angles.

The bigger picture

Tirzepatide was designed as a weight loss and diabetes drug. But the 2026 trials show it might be something else: a metabolic and reward system modulator that affects appetite, insulin sensitivity, inflammation, and potentially addiction.

We're still early. These trials need to complete and publish results. But the fact that researchers are testing tirzepatide for type 1 diabetes and alcohol use disorder signals a major shift in how we think about GLP-1 drugs.

They're not just weight loss drugs. They're tools for rewriting metabolic and neurological pathways.

Takeaways

• Tirzepatide produced 22.5% average weight loss in SURMOUNT-1. the highest of any drug
• Now being tested for type 1 diabetes with obesity across 80+ locations worldwide (NCT06914895)
• Also being tested for alcohol use disorder (NCT06994338) because GLP-1 receptors modulate brain reward pathways
• Weight maintenance trial shows some metabolic benefits persist even after stopping, but most people regain weight
• Combination therapy trials are testing tirzepatide + mibavademab to break through weight loss plateaus
• The shift in 2026: GLP-1 drugs are being repositioned as metabolic and reward system modulators, not just weight loss tools

This is educational content, not medical advice. Talk to your doctor before starting any protocol.